# Forward Pharmaceuticals

Source: https://onco.cc/companies/forward-pharmaceuticals/  
OnCo record `forward-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Forward Pharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of FWD1802 in HR-positive / HER2-negative breast cancer.

## Summary

Forward Pharmaceuticals, based in Shenzhen, China, is a biotechnology company. Forward Pharma is a clinical-stage biotechnology company focused exclusively on oncology drug development, using structural characterisation, biophysical profiling and computational optimisation. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing FWD1802 in HR-positive / HER2-negative breast cancer. The largest, NCT07002177 (A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC), plans to enrol 196 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Forward Pharmaceuticals Co., Ltd.
- Tags: ctgov-sponsor
- HQ: Shenzhen
- Type: biotech
- Website: https://www.forward-pharm.com

## Sources

- Official website: https://www.forward-pharm.com
- ClinicalTrials.gov: trials led by Forward Pharmaceuticals: https://clinicaltrials.gov/search?lead=Forward%20Pharmaceuticals%20Co.%2C%20Ltd.
- Pipeline page: https://www.forward-pharm.com/pipeline

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.](https://onco.cc/trials/nct06064812/), [A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC](https://onco.cc/trials/nct07002177/)

---
JSON: https://onco.cc/api/v1/entities/forward-pharmaceuticals.json